PhaseBio Pharmaceuticals announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent
for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects without report of drug-related serious adverse events.
Idarucizumab, a specific reversal agent
for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
The transaction will enable AMAG to acquire global rights of ciraparantag, a next generation anticoagulant reversal agent
, from Perosphere.
Shallow (TOFC=4; TOFR=0.1-0.4) and minimal (TOFC=4; TOFR >0.4 but <0.9) NMB should be reversed within 10 min after the application of the reversal agent
because of safety issues (47).
Dabigatran, the first novel oral anticoagulant (NOAC) with a neutralizing reversal agent
, ushered in a paradigm shift for the treatment of nonvalvular atrial fibrillation .
Idarucizumab (Praxbind) received FDA approval last October as a reversal agent
(3) Debaene et al., observed TOF ratios <0.7 and <0.9 postoperatively in 16% and 45% of patients respectively in the PACU, in patients receiving a single intubating dose of indermediate acting muscle but no reversal agent
at end of the procedure.
* The second major driver will be the approval and launch of the first antidotes for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent
in the event of uncontrolled bleeding, and will increase overall uptake.
Rr values indicate the cytotoxicity enhancement ratio, which can be used to quantify the potential power a MDR reversal agent
(http://usatoday30.usatoday.com/news/health/story/2012-08-19/pradaxa-blood-thinner-lawsuit/57134628/1) A March 6, 2012 report by the Journal of Neurosurgery warns there is no reversal agent
to stop fatal bleeding events in Pradaxa patients.
Whether sugammadex becomes the reversal agent
of choice non-selectively will depend on its eventual market price, the outcome of future trials, and further experience with its use.